documentation-naive
documentation-naive
Caring for Diabetes Home Page  
Search:
Home | Register or Login | Contact Us

No Sugar Coating Required: Real-Life Application of Incretin-Based Therapies in Type 2 Diabetes


No Sugar Coating Required: Real-Life Application of Incretin-Based Therapies in Type 2 Diabetes

Program Chair
James LaSalle, DO, FAAFP
Medical Director
Medical Arts Research Collaborative
Excelsior Springs, Missouri

Faculty
Derek LeRoith, MD, PhD
Professor of Medicine
Chief of the Division of Endocrinology,
Diabetes and Bone Disease
Mount Sinai School of Medicine
New York, New York

Jay Shubrook, DO, FACOFP, FAAFP
Associate Professor of Family Medicine
Director of Clinical Research
Director of Diabetes Fellowship
Department of Family Medicine
Ohio University
Heritage College of Osteopathic Medicine
Athens, Ohio

Activity Overview:
Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, provide effective glycemic control in type 2 diabetes (T2D), paired with beneficial nonglycemic effects on weight, lipids, and blood pressure. Additionally, these agents can be used in a wide variety of patients.

This unique program will highlight the comparative effectiveness and safety of these agents, appropriate patient selection, timely treatment initiation, and common barriers to glycemic control through the use of a simulated patient. The faculty will interview the patient, replicating an actual office visit. Supporting evidence will be presented to address the clinical concerns raised in the patient interview. At the conclusion of each talk, the faculty panel will discuss the case and offer clinical pearls and interviewing approaches to overcome patient-related barriers.

Intended Audience:
This activity is intended for osteopathic physicians who treat patients with T2D.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Identify patient barriers to early glycemic control in T2D
  • Explain the impact of early glycemic control on long-term microvascular and macrovascular risk in T2D
  • Review the mechanisms by which incretin-based therapies improve glycemic control
  • Compare and contrast the glycemic and nonglycemic effects of GLP-1 RAs and DPP-4 inhibitors
  • Apply clinical data and interviewing techniques to validate and overcome patient-related barriers to glycemic control

Program Agenda:
Talk 1: Type 2 Diabetes: What's the Big Deal?
Jay Shubrook, DO, FACOFP, FAAFP

Talk 2: Incretin-Based Therapies: An Introduction
James LaSalle, DO, FAAFP

Talk 3: Beyond Glycemic Control With Incretin-Based Therapies: Matching Patient Needs for Long-Term Success
Derek LeRoith, MD, PhD

Panel Discussion/Question-and-Answer Session

Credit Designation Statement:
For Physicians:
The American Osteopathic Associations (AOAs) has approved this activity for 2.5 hours of AOA Category 1-B credit.

For Nurses:
IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 2.5 contact hours (0.25 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Disclosures:
It is the policy of the AOA and the Institute for Medical and Nursing Education, Inc (IMNE) to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in content planning are expected to disclose any significant financial relationships with commercial interests over the past 12 months. It is also required that faculty identify and reference off-label product or investigational uses of pharmaceutical agents and medical devices.

The following disclosures have been made:

Faculty:
James LaSalle, DO, FAAFP

Speakers Bureau: AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Novo Nordisk Inc.
Consultant for Fee: AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Novo Nordisk Inc.

Dr LaSalle has disclosed that he will be discussing investigational uses of therapies, products, or devices.

Derek LeRoith, MD, PhD
Advisory Board: AstraZeneca; Bristol-Myers Squibb; Merck & Co, Inc; sanofi-aventis U.S. LLC.
Consultant: AstraZeneca; Bristol-Myers Squibb; Merck & Co, Inc; sanofi-aventis U.S. LLC

Dr LeRoith has disclosed that he will be discussing investigational uses of therapies, products, or devices.

Jay Shubrook, DO, FACOFP, FAAFP
Grant/Research Support: Eli Lilly and Company; sanofi-aventis U.S. LLC.

Dr Shubrook has disclosed that he does not anticipate discussing off-label or investigational uses of any therapies, products, or devices.

IMNE Staff
Amy Carbonara
Director, Program Development
IMNE
Ms Carbonara has nothing to disclose.

Robin Devine, DO
Medical Writer
IMNE
Mr Devine has nothing to disclose.

Katie Fidanza
Senior Program Coordinator
IMNE
Ms Fidanza has nothing to disclose.

Angela C McIntosh, PhD
Scientific Director
IMNE
Dr McIntosh has nothing to disclose.

Marge Tamas
Editorial Manager
IMNE
Ms Tamas has nothing to disclose.

Steve Weinman, RN
Executive Director
IMNE
Mr Weinman has nothing to disclose.

Patient/Actor
Thomas Fiocchi
Mr Fiocchi has nothing to disclose and he does not anticipate discussing off-label or investigational uses of any therapies, products, or devices.

Commercial Support Acknowledgment:
This activity is supported by an educational grant from Novo Nordisk Inc.

Method of Participation:
To obtain CME credit, each participant should:

  • View the content presented
  • Answer all questions posed throughout the activity
  • Complete and submit the CME demographic and evaluation form
  • Print the online CME certificate

This activity should take approximately 2.5 hours to complete. The expiration date for this activity is December 30, 2012. No credit will be granted after this date.

Minimum System Requirements:
The following system requirements are recommended for the best presentation viewing experience:

  • Microsoft Windows 2000, Windows XP, Windows 2003, Windows Vista, or Macintosh OS X
  • Display resolution of 800 x 600 pixels or greater
  • Windows-compatible sound card
  • Microsoft Internet Explorer 6.0 SP1.
  • Windows Media Player 9.0
  • Broadband Internet connection (256 Kbps & above)

For a complete list of system requirements needed to view the webcast please click here (this link opens a pdf document). If you have any questions about viewing the webcast please contact us.

Date of Original Release: Wednesday, November 2, 2011 (satellite symposium)
Release Date: December, 2011
Estimated Time to Complete this Activity: 2.5 hours

AOA
Sponsored by the American Osteopathic Association

IMNE
Developed by The Institute for Medical and Nursing Education, Inc.

ADA
Supported by an educational grant from Novo Nordisk Inc.

 I have read and understand the CME Information indexed above.

Webcast

CME/CE Posttest and Evaluation

    •  
    • CME/CE credit is offered upon successful completion of the posttest with a minimum passing score of 80%. The evaluation portion of this activity will be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • After completing the posttest and CME/CE evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.
    •  
    • Contact AOA for questions regarding AOA Category 1-B Credit: GLapin@osteopathic.org.
    • Contact IMNE for questions regarding ANCC Credits: steve.wieinman@imne.com.
    •  
    • CME Evaluation - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • CME Posttest - This should be completed after the demographic questionnaire.
    •  
About Us | Terms of Use | Privacy Statement | Disclaimer | Caring for Diabetes RSS News Feed Caring for Diabetes RSS News Feed